194 related articles for article (PubMed ID: 29336315)
1. A high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma.
Finon A; Zaragoza J; Maillard H; Beneton N; Bens G; Samimi M; Caille A; Machet L
Eur J Dermatol; 2018 Feb; 28(1):38-43. PubMed ID: 29336315
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.
Cassidy MR; Wolchok RE; Zheng J; Panageas KS; Wolchok JD; Coit D; Postow MA; Ariyan C
EBioMedicine; 2017 Apr; 18():56-61. PubMed ID: 28356222
[TBL] [Abstract][Full Text] [Related]
3. Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.
Schilling B; Sondermann W; Zhao F; Griewank KG; Livingstone E; Sucker A; Zelba H; Weide B; Trefzer U; Wilhelm T; Loquai C; Berking C; Hassel J; Kähler KC; Utikal J; Al Ghazal P; Gutzmer R; Goldinger SM; Zimmer L; Paschen A; Hillen U; Schadendorf D;
Ann Oncol; 2014 Mar; 25(3):747-753. PubMed ID: 24504444
[TBL] [Abstract][Full Text] [Related]
4. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
[TBL] [Abstract][Full Text] [Related]
6. High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors.
Teterycz P; Jagodzińska-Mucha P; Cybulska-Stopa B; Mariuk-Jarema A; Kozak K; Koseła-Paterczyk H; Czarnecka AM; Rajczykowski M; Dziura R; Galus Ł; Mackiewicz J; Świtaj T; Klimczak A; Falkowski S; Suwiński R; Ziobro M; Ługowska I; Rutkowski P
Melanoma Res; 2018 Oct; 28(5):435-441. PubMed ID: 29782381
[TBL] [Abstract][Full Text] [Related]
7. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
8. Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with outcome of patients treated with BRAF inhibitors.
Cocorocchio E; Martinoli C; Gandini S; Pala L; Conforti F; Stucchi S; Mazzarol G; Ferrucci P
Clin Transl Oncol; 2020 Oct; 22(10):1818-1824. PubMed ID: 32108276
[TBL] [Abstract][Full Text] [Related]
9. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma.
Zaragoza J; Caille A; Beneton N; Bens G; Christiann F; Maillard H; Machet L
Br J Dermatol; 2016 Jan; 174(1):146-51. PubMed ID: 26343230
[TBL] [Abstract][Full Text] [Related]
10. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
[TBL] [Abstract][Full Text] [Related]
11. Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.
Puszkiel A; White-Koning M; Dupin N; Kramkimel N; Thomas-Schoemann A; Noé G; Chapuis N; Vidal M; Goldwasser F; Chatelut E; Blanchet B
Pharmacol Res; 2016 Nov; 113(Pt A):709-718. PubMed ID: 27378568
[TBL] [Abstract][Full Text] [Related]
12. Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.
Amaravadi RK; Hamilton KE; Ma X; Piao S; Portillo AD; Nathanson KL; Carlino MS; Long GV; Puzanov I; Xu X; Morrissette JJ; Tsai KY; Flaherty KT; Sosman JA; Goodman GR; McArthur GA; Rustgi AK; Metz DC; Schuchter LM; Chapman PB; Sepulveda AR
Clin Cancer Res; 2015 Dec; 21(23):5215-21. PubMed ID: 26202952
[TBL] [Abstract][Full Text] [Related]
13. Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?
Tolk H; Satzger I; Mohr P; Zimmer L; Weide B; Schäd S; Gutzmer R
Melanoma Res; 2015 Aug; 25(4):362-6. PubMed ID: 26061438
[TBL] [Abstract][Full Text] [Related]
14. Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report.
Orouji E; Ziegler B; Umansky V; Gebhardt C; Utikal J
Medicine (Baltimore); 2014 Dec; 93(28):e161. PubMed ID: 25526431
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
Schaper-Gerhardt K; Okoye S; Herbst R; Ulrich J; Terheyden P; Pföhler C; Utikal JS; Kreuter A; Mohr P; Dippel E; Satzger I; Sucker A; Schadendorf D; Ugurel S; Gutzmer R
Eur J Cancer; 2018 Jan; 88():67-76. PubMed ID: 29195116
[TBL] [Abstract][Full Text] [Related]
16. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
17. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment.
Ly D; Bagshaw HP; Anker CJ; Tward JD; Grossmann KF; Jensen RL; Shrieve DC
J Neurosurg; 2015 Aug; 123(2):395-401. PubMed ID: 25768829
[TBL] [Abstract][Full Text] [Related]
18. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.
Massi D; Romano E; Rulli E; Merelli B; Nassini R; De Logu F; Bieche I; Baroni G; Cattaneo L; Xue G; Mandalà M
Eur J Cancer; 2017 Jun; 78():70-81. PubMed ID: 28412591
[TBL] [Abstract][Full Text] [Related]
19. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
20. [New treatment options for metastatic melanoma].
Tietze JK; Berking C
Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
[No Abstract] [Full Text] [Related]
[Next] [New Search]
